Cash Flow Statement

Amortizatization of Intangibles Amortizatization of Intangibles Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Change in Taxes Change in Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Share-based Compensation Share-based Compensation Shares Issued Short-Term Debt repayments

Daily Values

Growth Metrics

Others

Apellis Pharmaceuticals (APLS) Amortization of Deferred Charges (2020 - 2021)

Apellis Pharmaceuticals filings provide 2 years of Amortization of Deferred Charges readings, the most recent being $3000.0 for Q4 2021.

For the quarter ending Q4 2021, Amortization of Deferred Charges fell 76.92% year-over-year to $3000.0, compared with a TTM value of $113000.0 through Dec 2021, down 49.1%, and an annual FY2021 reading of $113000.0, down 49.1% over the prior year.
Amortization of Deferred Charges hit $3000.0 in Q4 2021 for Apellis Pharmaceuticals, up from -$8000.0 in the prior quarter.
The five-year high for Amortization of Deferred Charges was $125000.0 in Q3 2020, with the low at -$8000.0 in Q3 2021.